Prostate

Papers
(The H4-Index of Prostate is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
54
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level36
Erratum to “Inhibition of Signaling Downstream of Beta‐2 Adrenoceptor by Propranolol in Prostate Cancer Cells”31
Impact of androgen receptor alterations on cell‐free DNA genomic profiling on survival outcomes in metastatic castration‐resistant prostate cancer27
VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach26
Prognostic factors of overall and prostate‐specific antigen‐progression‐free survival in metastatic castration‐resistant prostate cancer patients treated with 177Lu‐PSMA‐617. A single‐cente26
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review25
Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy24
Comprehensive Genomic Profiling Testing for Castration‐Resistant Prostate Cancer in Advanced Elderly Patients: A Single‐Center Retrospective Cohort Study23
The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer21
21
Investigation of pelvic floor influence on prostate displacement in image‐guided radiotherapy20
3βHSD activity saturates at physiological substrate concentrations in intact cells20
A west African ancestry‐associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening20
Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity20
Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers: A Matched‐Pair Analysis19
19
Strong PD‐L1 expression in granulomatous prostatitis18
Issue Information18
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study18
0.1115620136261